Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Seres’s success with an industrially made bacterial mix in phase 3 trials against Clostridium difficile infection promises an alternative to fecal microbial transplantation in clinical practice.
The first antibody–drug conjugate to treat multiple myeloma can spur reversible loss of vision, but that may not be the case for other anti-BCMA T-cell therapies or bispecific antibodies.
Social quarantine has severely impacted the training of new scientists, but the use of virtual platforms can supplement mentorship, making career development seamless.
Rapid progress is being made in our understanding of RNA–protein interactions, their role in disease and their influence on the action of oligonucleotide drugs.
The race to bring vaccines to market is nearing the finish line. Determining which product can best contain the pandemic, however, will take more time.